One such agent, RP2, an enhanced-potency oncolytic HSV-1-expressing human granulocyte-macrophage colony-stimulating factor, a Gibbon Ape Leukemia Virus glycoprotein (GALV-GP-R−), and an anti-CTLA-4 antibody-like molecule, has demonstrated a 29.4% overall response rate in a phase I trial, including 17 patients with advanced uveal melanoma, both as monotherapy and in combination with nivolumab116. This evidence concerns the gene CSF2 and uveal melanoma.